DURECT Corporation Reports First Quarter 2001 Financial Results

Download PDF:

CUPERTINO, Calif., April 30 /PRNewswire/ —
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the
three months ended March 31, 2001.

The company’s net loss attributable to common stockholders for the three
months ended March 31, 2001 was $4.9 million or 11 cents per share, compared
to $4.7 million, or 71 cents per share, for the three months ended March 31,
2000. DURECT’s results include non-cash charges for the amortization of
intangible assets and stock-based compensation of $1.2 million for the three
months ended March 31, 2001 and $1.2 million for the same period in 2000.

Commenting on the first quarter results, James E. Brown, CEO of DURECT
stated, “We are pleased with the company’s progress over the quarter. We have
completed patient enrollment for our Phase II clinical trial for DUROS
sufentanil more than three months ahead of schedule. We have a long-term
supply agreement with Mallinckrodt to supply DURECT’s clinical and commercial
requirements for sufentanil. The construction of our commercial manufacturing
facility is on track for completion in the second quarter of 2001. Each of
these accomplishments represents a significant step towards initiating our
Phase III clinical trial, and towards bringing our products to market. Today,
we also announced our acquisition of Southern BioSystems, a developer,
manufacturer and supplier of biodegradable polymer and non-polymer drug
delivery systems. With this acquisition, we have added three additional drug
delivery platforms, the SABER(TM) delivery system, microspheres and
drug-loaded implants, which will allow us to move additional products into
development. These technology platforms, which enable delivery of drugs from
days to months, are very complementary to our existing DUROS(R) business,
which has a therapeutic delivery profile from months to a year.”

The increase in net loss for the first quarter of 2001 compared to the
first quarter of 2000 was primarily due to increased research and development
activity, especially related to the company’s Phase II clinical trial for its
lead product, DUROS sufentanil. As a result of the early completion of
patient enrollment for this trial, the company accelerated related expenses in
the first quarter of 2001. The increase in operating expenses was offset by
increased interest income resulting from higher average outstanding cash
balances, and by an increase in gross profit resulting from product sales.

At March 31, 2001, the company had cash and investments of $102.1 million
compared to $41.1 million at March 31, 2000. This increase was primarily due
to the proceeds from the sale of common stock from DURECT’s initial public
offering, which closed on October 3, 2000.

DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems to deliver the right drug to the right site in the
right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.

In addition to DUROS sufentanil, DURECT’s second product in development,
DUROS hydromorphone, is a DUROS-based pharmaceutical system for the delivery
of hydromorphone to the spine. DURECT is also selling FDA cleared catheters
for the delivery of fluids to the inner ear. DURECT also manufactures, sells
and distributes the ALZET(R) osmotic pump product for use in laboratory
research. SABER(TM) is a trademark of Southern BioSystems, Inc., a subsidiary
of DURECT Corporation.

Founded in 1998, DURECT is headquartered in Cupertino, CA. The company’s
World Wide Web site can be accessed at http://www.www.durect.com. To join
DURECT’s email alert service, please register by selecting “Email Alerts” on
the main Investor Relations web page at http://www.www.durect.com.

DUROS is a registered trademark of ALZA Corporation.

                              DURECT CORPORATION
                    (in thousands, except per share amounts)

                                                        Quarter ended
                                                           March 31,
                                                     2001              2000
                                                 (unaudited)       (unaudited)

    Revenue, net                                    $1,399               $83
    Cost of goods sold (1)                             611                36
    Gross profit                                       788                47

    Operating expenses:
          Research and development                   4,094             2,259
          Research and development to
           related party                                47               262
          Selling, general and
           administrative                            1,878               970
          Amortization of intangible
           assets                                      274                69
          Stock-based compensation (1)                 935             1,132
    Total operating expenses                         7,228             4,692
    Loss from operations                            (6,440)           (4,645)

    Other income (expense):
          Interest income                            1,584               287
          Interest expense                             (62)              (21)
    Net other income                                 1,522               266
    Net Loss                                        (4,918)           (4,379)

    Accretion of cumulative dividends on
     Series B
      convertible preferred stock                        --             (326)
    Net loss attributable to common
     stockholders                                  $(4,918)          $(4,705)

    Net loss per common share, basic and
     diluted                                        $(0.11)           $(0.71)

    Shares used in computing basic and
     diluted net loss per share                     45,128             6,604

    Pro forma net loss per share, basic
     and diluted (2)                                                  $(0.14)

    Shares used in computing pro forma
     net loss per share (2)                                           30,653

    (1) Stock-based compensation related to the following:

    Cost of goods sold                                 $22              $--
    Research and development                           680               705
    Selling, general and administrative                255               427
                                                      $957            $1,132

    (2) Pro forma calculations assume the conversion of all preferred stock,
        at the date of issuance, into common stock.

                              DURECT CORPORATION
                           CONDENSED BALANCE SHEET
                                (in thousands)

                                                               March 31,
                                                          2001        2000
    Current assets:
     Cash, cash equivalents and short-term
      investments                                        $85,036      $40,141
     Inventories and other current assets                  5,074          705
    Total current assets                                  90,110       40,846

    Property and equipment, net                            5,724        1,578
    Intangible assets, net                                 4,901        1,320
    Long-term investments and
     other non-current assets                             17,090        1,256

    Total assets                                        $117,825      $45,000

    Liabilities and stockholders' equity
    Current liabilities:
     Accounts payable and accrued liabilities             $4,872       $1,455
     Equipment financing obligations,
      current portion                                        475          225
    Total current liabilities                              5,347        1,680

    Equipment financing obligations,
     noncurrent portion                                      961          611

    Stockholders' equity                                 111,517       42,709

    Total liabilities and stockholders' equity          $117,825      $45,000

The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials, and expected product
benefits are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but
are not limited to, DURECT’s ability to develop, manufacture and commercialize
its products, complete successful clinical trials, obtain product approvals
from regulatory agencies, build a manufacturing facility, manage its growth
and costs, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in the company’s S-1
registration statement, filed with the SEC on September 22, 2000, 424(b)
prospectus filed with the SEC on September 28, 2000, Quarterly Report on Form
10-Q for the quarter ended September 30, 2000 filed with the SEC on November
14, 2000 and Annual Report on Form 10-K for the fiscal year ended December 31,
2000 filed with the SEC on March 30, 2001.

CONTACT: For further information please contact:
DURECT Corporation
Schond L. Greenway
Director, Investor Relations
Phone: 408-777-1417
                    MAKE YOUR OPINION COUNT -  Click Here


CONTACT: Schond L. Greenway, Director, Investor Relations, DURECT
Corporation, 408-777-1417, schond.greenway@durect.com/

Scroll to Top